Brentuximab vedotin in the treatment of relapsed CD30 positive cutaneous lymphoma - results of an international, open label, randomised, phase 3, multicentre trial - ALCANZA | Zendy

AI Assistant Blog Pricing

Brentuximab vedotin in the treatment of relapsed CD30 positive cutaneous lymphoma - results of an international, open label, randomised, phase 3, multicentre trial - ALCANZA

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.